Alternative Medicine Business Investment Opportunities in Dublin

Promoter experience: - The CEO brings 12+ years of pharmaceutical commercialisation and GTM strategy across EU and GCC markets, with experience leading €40M+ product launches through Temple Group. The scientific and clinical advisory team draws on backgrounds from Pfizer, TCD, RCSI, the Pasteur Institute, and NCRI. Scientific foundation: - The platform is built on 3,400+ peer-reviewed studies on core bioactive compounds — azadirachtin, gedunin, nimbin, and nimbolide — published between the last 25 years. - Efficacy is scientifically established; the patent landscape remains open. Revenue model: - Three streams in sequence: Direct-to-consumer and pharmacy sales (from Year 1), prescription therapeutics and clinical licensing (from Year 2), and molecule licensing and pharma co-development agreements (from Year 3). 15% of net profit is ring-fenced annually into R&D. IP & regulatory positioning: - Patent filings on novel botanical molecule derivatives are planned within 18 months of production launch. Ireland's Knowledge Development Box provides a 6.25% effective tax rate on qualifying patent income which is a structural advantage for an IP-led business. Incorporation: - We are an registered Irish company, incorporated in Dublin, with full corporate documentation in place. Stage: - Pre-revenue, pre-clinical, with the lead product (psoriasis cream) entering production this year.

Promoter experience: - The CEO brings 12+ years of pharmaceutical commercialisation and GTM strategy across EU and GCC markets, with experience leading €40M+ product launches through Temple Group. The scientific and clinical advisory team draws on backgrounds from Pfizer, TCD, RCSI, the Pasteur Institute, and NCRI. Scientific foundation: - The platform is built on 3,400+ peer-reviewed studies on core bioactive compounds — azadirachtin, gedunin, nimbin, and nimbolide — published between the last 25 years. - Efficacy is scientifically established; the patent landscape remains open. Revenue model: - Three streams in sequence: Direct-to-consumer and pharmacy sales (from Year 1), prescription therapeutics and clinical licensing (from Year 2), and molecule licensing and pharma co-development agreements (from Year 3). 15% of net profit is ring-fenced annually into R&D. IP & regulatory positioning: - Patent filings on novel botanical molecule derivatives are planned within 18 months of production launch. Ireland's Knowledge Development Box provides a 6.25% effective tax rate on qualifying patent income which is a structural advantage for an IP-led business. Incorporation: - We are an registered Irish company, incorporated in Dublin, with full corporate documentation in place. Stage: - Pre-revenue, pre-clinical, with the lead product (psoriasis cream) entering production this year.